Early-Life Prevention of Cardiovascular-Kidney-Metabolic Syndrome: The DOHaD Perspective on Resveratrol and

Chien-Ning Hsu1,2,3, Ying-Jui Lin4,5,6,7, Chih-Yao Hou8

  • 1Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.

Insights

Early life interventions targeting oxidative stress and gut dysbiosis show promise for preventing cardiovascular-kidney-metabolic (CKM) syndrome. Preclinical studies highlight antioxidants like resveratrol and short-chain fatty acids (SCFAs) for CKM conditions.

Area of Science:

  • Integrative biology
  • Developmental origins of health and disease (DOHaD)
  • Nutritional science

Background:

  • Cardiovascular-kidney-metabolic (CKM) syndrome links cardiovascular, kidney, and metabolic diseases.
  • Emerging evidence suggests CKM syndrome may originate in early life, aligning with DOHaD principles.
  • Perinatal oxidative stress and gut dysbiosis are implicated in CKM development.

Purpose of the Study:

  • To review preclinical findings on early-life factors influencing CKM syndrome.
  • To examine the role of antioxidants (resveratrol) and gut microbiota modulators (SCFAs) in animal models.
  • To identify the translational gap for early-life interventions in CKM syndrome.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of animal models investigating perinatal oxidative stress and gut dysbiosis.
  • Evaluation of resveratrol, SCFAs, and their derivatives in mitigating CKM conditions.

Main Results:

  • Animal studies demonstrate that resveratrol and SCFAs can modulate gut microbiota and oxidative stress.
  • Resveratrol derivatives show improved bioavailability in preclinical models.
  • Early-life interventions targeting these pathways show potential in mitigating CKM development.

Conclusions:

  • Preclinical evidence supports early-life interventions for CKM syndrome prevention.
  • Resveratrol and SCFAs show promise in modulating key risk factors.
  • Human studies are crucial to validate these findings and bridge the translational gap.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
35
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
58
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
73